Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Patrizia Pregno"'
Autor:
Valentina Giai, Matteo Bisio, Tiziana Rosso, Irene Urbino, Chiara Frairia, Matteo Olivi, Giuseppe Lanzarone, Mattia D’agostino, Eloise Beggiato, Stefano D’ ardia, Ernesta Audisio, Marco Cerrano, Dario Ferrero, Patrizia Pregno, Roberto Freilone
Publikováno v:
HemaSphere, Vol 7, p e6848349 (2023)
Externí odkaz:
https://doaj.org/article/27350578be1845d7b27527d2d16ecfd9
Autor:
Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 14, Iss 1 (2022)
Systemic mastocytosis (SM) is a rare disease with a range of clinical presentations, and the vast majority of patients have a KIT D816V mutation that results in gain of function. The multikinase/KIT inhibitor midostaurin inhibits the D816V mutant, an
Externí odkaz:
https://doaj.org/article/591175367f194fbdafbf36f07a298b52
Autor:
Alessandra Iurlo, Daniele Cattaneo, Silvia Artuso, Dario Consonni, Elisabetta Abruzzese, Gianni Binotto, Monica Bocchia, Massimiliano Bonifacio, Fausto Castagnetti, Sara Galimberti, Antonella Gozzini, Miriam Iezza, Roberto Latagliata, Luigiana Luciano, Alessandro Maggi, Maria Cristina Miggiano, Patrizia Pregno, Giovanna Rege-Cambrin, Sabina Russo, Anna Rita Scortechini, Agostino Tafuri, Mario Tiribelli, Carmen Fava, Gianantonio Rosti, Robin Foa, Massimo Breccia, Giuseppe Saglio
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction is often used in real-life practice to reduce adverse events, although its impact on TFR is s
Externí odkaz:
https://doaj.org/article/65c0695e402745059fa9fbd7d9d31204
Autor:
Simona Soverini, Elisabetta Abruzzese, Monica Bocchia, Massimiliano Bonifacio, Sara Galimberti, Antonella Gozzini, Alessandra Iurlo, Luigiana Luciano, Patrizia Pregno, Gianantonio Rosti, Giuseppe Saglio, Fabio Stagno, Mario Tiribelli, Paolo Vigneri, Giovanni Barosi, Massimo Breccia
Publikováno v:
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-11 (2019)
Abstract BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine kinase inhibitors (TKIs). Con
Externí odkaz:
https://doaj.org/article/4a0beae3db7740d48a6fa4a15e2f69bd
Autor:
Giorgina Specchia, Patrizia Pregno, Massimo Breccia, Fausto Castagnetti, Chiara Monagheddu, Massimiliano Bonifacio, Mario Tiribelli, Fabio Stagno, Giovanni Caocci, Bruno Martino, Luigiana Luciano, Michele Pizzuti, Antonella Gozzini, Anna Rita Scortechini, Francesco Albano, Micaela Bergamaschi, Isabella Capodanno, Andrea Patriarca, Carmen Fava, Giovanna Rege-Cambrin, Federica Sorà, Sara Galimberti, Monica Bocchia, Gianni Binotto, Giovanni Reddiconto, Paolo DiTonno, Alessandro Maggi, Grazia Sanpaolo, Maria Stella De Candia, Valentina Giai, Elisabetta Abruzzese, Maria Cristina Miggiano, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, Luciano Levato, Olga Mulas, Fabio Saccona, Gianantonio Rosti, Pellegrino Musto, Francesco Di Raimondo, Fabrizio Pane, Michele Baccarani, Giuseppe Saglio, Giovannino Ciccone
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
An observational prospective study was conducted by the CML Italian network to analyze the role of baseline patient characteristics and first line treatments on overall survival and CML-related mortality in 1206 newly diagnosed CML patients, 608 trea
Externí odkaz:
https://doaj.org/article/80fae6bf631f4cfeacf02aac94eccb84
Autor:
Federica Loscocco, Giuseppe Visani, Annamaria Ruzzo, Irene Bagaloni, Fabio Fuligni, Sara Galimberti, Antonello Di Paolo, Fabio Stagno, Patrizia Pregno, Mario Annunziata, Antonella Gozzini, Sara Barulli, Elisa Gabucci, Mauro Magnani, Alessandro Isidori
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of
Externí odkaz:
https://doaj.org/article/43ad989d92e946a3a061a8934831529a
Autor:
Mario Annunziata, Massimiliano Bonifacio, Massimo Breccia, Fausto Castagnetti, Antonella Gozzini, Alessandra Iurlo, Patrizia Pregno, Fabio Stagno, Giorgina Specchia
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close mo
Externí odkaz:
https://doaj.org/article/6498090076d94b349386a48a428cef6f
Publikováno v:
Medicina, Vol 57, Iss 10, p 1043 (2021)
Philadelphia negative Myeloproliferative Neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell diseases. MPNs show different risk grades of thrombotic complications and acute myeloid leukemia evolution. In the last couple of decades, f
Externí odkaz:
https://doaj.org/article/f1e9aacf1835450b93c3701781e1fa03
Autor:
Mohammad Houshmand, Francesca Garello, Rachele Stefania, Valentina Gaidano, Alessandro Cignetti, Michela Spinelli, Carmen Fava, Mahin Nikougoftar Zarif, Sara Galimberti, Ester Pungolino, Mario Annunziata, Luigia Luciano, Giorgina Specchia, Monica Bocchia, Gianni Binotto, Massimiliano Bonifacio, Bruno Martino, Patrizia Pregno, Fabio Stagno, Alessandra Iurlo, Sabina Russo, Silvio Aime, Paola Circosta, Giuseppe Saglio
Publikováno v:
Cancers, Vol 13, Iss 6, p 1311 (2021)
CML is a hematopoietic stem-cell disorder emanating from breakpoint cluster region/Abelson murine leukemia 1 (BCR/ABL) translocation. Introduction of different TKIs revolutionized treatment outcome in CML patients, but CML LSCs seem insensitive to TK
Externí odkaz:
https://doaj.org/article/0a896ef93d264e3eb697531571e1d565
Autor:
Roberto Latagliata, Fabio Stagno, Mario Annunziata, Elisabetta Abruzzese, Alessandra Iurlo, Attilio Guarini, Carmen Fava, Antonella Gozzini, Massimiliano Bonifacio, Federica Sorà, Sabrina Leonetti Crescenzi, Monica Bocchia, Monica Crugnola, Fausto Castagnetti, Isabella Capodanno, Sara Galimberti, Costanzo Feo, Raffaele Porrini, Patrizia Pregno, Manuela Rizzo, Agostino Antolino, Endri Mauro, Nicola Sgherza, Luigiana Luciano, Mario Tiribelli, Antonella Russo Rossi, Malgorzata Trawinska, Paolo Vigneri, Massimo Breccia, Gianantonio Rosti, Giuliana Alimena
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 536-540 (2016)
Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we
Externí odkaz:
https://doaj.org/article/cf326cb4083d49d69854ac476b662cf8